Literature DB >> 18083478

Dolasetron-induced torsades de pointes.

Sarah Turner1, Letha Mathews, Pratik Pandharipande, Reid Thompson.   

Abstract

A 52-year-old woman with hypertension and Graves' disease was scheduled for surgical removal of a meningioma. Intraoperative events were significant for hypotension requiring a vasopressin infusion. Prophylactic dolasetron was administered to the patient before emergence. The patient's trachea was easily extubated and she was neurologically intact at the end of the surgical procedure. On transport to the neurological intensive care unit, the patient developed torsades de pointes, requiring cardiopulmonary resuscitation, before a return to normal sinus rhythm.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18083478     DOI: 10.1016/j.jclinane.2007.03.012

Source DB:  PubMed          Journal:  J Clin Anesth        ISSN: 0952-8180            Impact factor:   9.452


  7 in total

Review 1.  QT interval abnormalities: risk factors and perioperative management in long QT syndromes and Torsades de Pointes.

Authors:  Alan David Kaye; Jacqueline Volpi-Abadie; J Michael Bensler; Adam M Kaye; James H Diaz
Journal:  J Anesth       Date:  2013-02-15       Impact factor: 2.078

Review 2.  State of the Art Antiemetic Therapy for Cancer Patients.

Authors:  Thomas K H Lau; Claudia H W Yip; Winnie Yeo
Journal:  Curr Oncol Rep       Date:  2016-01       Impact factor: 5.075

Review 3.  Perioperative torsade de pointes: a systematic review of published case reports.

Authors:  Joshua Johnston; Swatilika Pal; Peter Nagele
Journal:  Anesth Analg       Date:  2013-06-06       Impact factor: 5.108

4.  [Perioperative treatment of patients with long QT syndrome].

Authors:  T Krönauer; P Friederich
Journal:  Anaesthesist       Date:  2015-08       Impact factor: 1.041

5.  Reappraisal of the role of dolasetron in prevention and treatment of nausea and vomiting associated with surgery or chemotherapy.

Authors:  S Michael Roberts; Dmitri S Bezinover; Piotr K Janicki
Journal:  Cancer Manag Res       Date:  2012-02-24       Impact factor: 3.989

6.  Early Drug Discovery Prediction of Proarrhythmia Potential and Its Covariates.

Authors:  Sebastian Polak; Michael K Pugsley; Norman Stockbridge; Christine Garnett; Barbara Wiśniowska
Journal:  AAPS J       Date:  2015-05-05       Impact factor: 4.009

7.  Effect of single doses of IV palonosetron, up to 2.25 mg, on the QTc interval duration: a double-blind, randomized, parallel group study in healthy volunteers.

Authors:  Joel Morganroth; Kristen K Flaharty; Simona Parisi; Cecilia Moresino
Journal:  Support Care Cancer       Date:  2015-06-26       Impact factor: 3.603

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.